Cell Chemical Biology

Research Funded by Bay Area Lyme Foundation Identifies New Investigational Therapy Regimen Capable of Irreversibly Damaging Lyme Bacteria in Laboratory Tests

Retrieved on: 
Wednesday, November 1, 2023
Linda, Knowledge, Lyme disease, University of California, Davis, Stanford University, Infection, UC, Obesity, MD, University of North Carolina, Doctor of Philosophy, Research, Light, Protein, Duke University School of Medicine, Borrelia burgdorferi, Medicine, Hypertension, Immunotherapy, Bacteria, University, Cell Chemical Biology, Cancer, Hsp90, Cell wall, Patient, Tulane University, DNA, Fatigue, Pharmaceutical industry, Vaccine, Pharmacology

“Bay Area Lyme concentrates on funding innovative research, including projects where knowledge can be deployed from other areas of medicine.

Key Points: 
  • “Bay Area Lyme concentrates on funding innovative research, including projects where knowledge can be deployed from other areas of medicine.
  • He encouraged scientists to take cancer staging techniques and immunotherapy learnings from oncology and apply them to Lyme research.
  • Bay Area Lyme Foundation also funded University of North Carolina collaborator, Matt Redinbo , PhD’s research on HS-291; his lab’s crystallography work was instrumental in the discovery process.
  • Bay Area Lyme Foundation’s research grant program was made possible by the support from the Fairbairn Family, the Younger Family Fund, and Project Lyme .

Cell-Based Assays Reveal Two Reported Anti-Inflammation Molecules Fail to Engage Target Protein

Retrieved on: 
Wednesday, October 25, 2023
Research, Other Health, General Health, Pharmaceutical, Medical Devices, Hospitals, Clinical Trials, Science, Biotechnology, Stem Cells, FDA, Health, Other Science, Cell Chemical Biology, Inflammation, NLRP3, Therapy, Löffler's syndrome, Drug development, Pharmaceutical industry

A new study uses key Promega technologies to evaluate reported anti-inflammation molecules in the context of live cells.

Key Points: 
  • A new study uses key Promega technologies to evaluate reported anti-inflammation molecules in the context of live cells.
  • Promega research scientists used three unique assays to evaluate seven inhibitors targeting the NLRP3 inflammasome, a hot target in drug development for its role in multiple inflammatory diseases.
  • The team was able to rank the potency of five reported NLRP3 inhibitors and demonstrate that two failed to produce the intended biological effects.
  • Based on the results of these assays, the team determined that two reported inhibitors did not engage NLRP3 or functionally inhibit the target pathway.

Quantum-Si Appoints Biotech Executive and Entrepreneur, Amir Jafri, to its Board of Directors

Retrieved on: 
Thursday, September 21, 2023
Health, General Health, Munich Information Center for Protein Sequences, Houston Christian University, Cancer, Protein sequencing, Multimedia, Proteomics, Organization, Cardinal Health, Cell Chemical Biology, Biology, ManpowerGroup, Management, Science, History, Chemistry, West Health

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the appointment of Amir Jafri, President and CEO of Immunicom, Inc., to its Board of Directors.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the appointment of Amir Jafri, President and CEO of Immunicom, Inc., to its Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20230921747791/en/
    “Amir’s leadership track record speaks for itself,” said Jeff Hawkins, CEO of Quantum-Si.
  • Previously, Mr. Jafri held executive leadership positions at West Health, Cardinal Health and the Manpower Group.
  • Mr. Jafri is an inventor on over 40 patents covering products and technologies across a range of industries and applications.

City of Hope scientists develop targeted chemotherapy able to kill all solid tumors in preclinical research

Retrieved on: 
Tuesday, August 1, 2023
Linda, Molecule, Alex's Lemonade Stand Foundation, DNA, Rituximab, Insulin, Human, City of Hope National Medical Center, City of Hope, R01, Neoplasm, Biotechnology, Cell Chemical Biology, Trastuzumab, Clinical trial, Ovary, Breast, Toxicity, Brain, Research, Gene expression, Prostate, Treatment of lung cancer, Cell, Molecular diagnostics, Translational Genomics Research Institute, Cetuximab, Experiment, RLL, Bangladesh Technical Education Board, DNA replication, National Cancer Institute, S phase, Australian Melanoma Research Foundation, Patient, Department of Defense Serum Repository, Apoptosis, LOS, Beckman Research Institute, Proliferating cell nuclear antigen, Therapy, Skin, PCNA, Vaccine, Pharmaceutical industry, Molecular oncology, City, Hope

LOS ANGELES, Aug. 1, 2023 /PRNewswire/ -- Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, today published a new study explaining how they took a protein once thought to be too challenging for targeted therapy, proliferating cell nuclear antigen (PCNA), and developed a targeted chemotherapy that appears to annihilate all solid tumors in preclinical research. As the scientists continue to investigate the foundational mechanisms that make this cancer-stopping pill work in animal models, they note that there is an ongoing Phase 1 clinical trial testing the City of Hope-developed therapeutic in humans.

Key Points: 
  • Data suggests PCNA is uniquely altered in cancer cells, and this fact allowed us to design a drug that targeted only the form of PCNA in cancer cells.
  • The investigational chemotherapeutic is currently in a Phase 1 clinical trial in humans at City of Hope."
  • Now that we know the problem area and can inhibit it, we will dig deeper to understand the process to develop more personalized, targeted cancer medicines."
  • "City of Hope has world leaders in cancer research.

DNA-Encoded Libraries (DELs) and NanoBRET Target Engagement Assays Accelerate Drug Discovery

Retrieved on: 
Tuesday, August 1, 2023
Biotechnology, Other Health, Health, Science, Research, DNA, Partnership, Therapy, Aurora kinase A, Workflow, Cell Chemical Biology, Dels, Structural Genomics Consortium, Promega, Protein, DEL, Cancer, Drug discovery, Wuxi, Pharmaceutical industry, Microscope

A new study demonstrates how the combination of DNA-encoded libraries (DELs) and NanoBRET Target Engagement technology can accelerate early-stage drug discovery.

Key Points: 
  • A new study demonstrates how the combination of DNA-encoded libraries (DELs) and NanoBRET Target Engagement technology can accelerate early-stage drug discovery.
  • This research opens new opportunities to develop novel NanoBRET Target Engagement Assays aimed at many understudied classes of proteins, rapidly accelerating “hit to lead” efforts in identifying new potential therapeutics.
  • These probes would be used in a NanoBRET Target Engagement Assay, a tool for studying the interaction between a chemical compound and its target protein in live cells.
  • Additionally, they note that the NanoBRET assays help drug discovery researchers accelerate their workflow by providing data used to identify the most promising leads.

Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors

Retrieved on: 
Thursday, December 29, 2022
Reg, Coury, University, International Management Institute, New Delhi, COVID-19, ICU Medical, Audit committee, Celgene, Regulation Fair Disclosure, Patient, Golden Gate University, Partnership, Pandemic, SVP, Risk management, Marketing, Upjohn, Insurance, Cell Chemical Biology, Therapy, Inflammation, MS, American Graduate School in Paris, Housing, Communities and Local Government Committee, Growth, Conditional, Multimedia, Biology, Combination, Software, Smith, Cancer, Epidemic, Bachelor of Science, Organization, Security (finance), Annual Review of Pharmacology and Toxicology, Varian Medical Systems, Retirement, NanoString Technologies, Toxicology, Pfizer, Management, Pharmaceutical industry, Pharmacology, Viatris, Varian, Chemistry, Immunology

PITTSBURGH, Dec. 29, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Scott A. Smith and Elisha W. Finney have been appointed as Viatris' newest members of its board of directors. Smith and Finney fill the vacancies created by the retirement of Neil Dimick and Ian Reid.

Key Points: 
  • PITTSBURGH, Dec. 29, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Scott A. Smith and Elisha W. Finney have been appointed as Viatris' newest members of its board of directors.
  • Coury continued, "We are also pleased to welcome Scott Smith and Elisha Finney to the board.
  • We look forward to working with both Scott and Elisha and the contributions that each will bring to our board."
  • Ian Read stated, "I have sincerely appreciated my time on the Viatris board of directors since the Combination.

Prolifagen Therapeutics Appoints M. Alexander Shaw, PhD, as Chief Executive Officer

Retrieved on: 
Tuesday, September 13, 2022
Therapy, University, Sale, Muscle tissue, Washington State University, Cell Chemical Biology, MicroRNA, Heart failure, Myocardial infarction diagnosis, Regeneration, Patient, Duke University, Running, Doctor of Philosophy, Drug development, Pharmacology, American Heart, Board, Chairperson, Infarction, Biophysics, American Heart Association, Fear, Biology, Pharmaceutical industry, Chemistry, Biochemistry

VILLANOVA, Pa., Sept. 13, 2022 /PRNewswire/ -- Prolifagen Therapeutics, a biotech startup developing medicines for cardiac regeneration, has appointed M. Alexander Shaw, PhD, as Chief Executive Officer.

Key Points: 
  • VILLANOVA, Pa., Sept. 13, 2022 /PRNewswire/ -- Prolifagen Therapeutics, a biotech startup developing medicines for cardiac regeneration, has appointed M. Alexander Shaw, PhD, as Chief Executive Officer.
  • In this role, Dr. Shaw will lead Prolifagen's efforts in bringing new medicines to market to prevent development of heart failure in patients with large myocardial infarcts.
  • Dr. Shaw succeeds Claudine Bruck, PhD, who co-founded Prolifagen and successfully led it through initial pre-clinical studies of its microRNA therapeutic, miR-302.
  • Founded in 2016, Prolifagen is an early-stage biotech startup whose mission is to prevent the development of heart failure in patients with large myocardial infarcts.

Rubedo Life Sciences Expands Leadership Team with Ali Siam as Chief Business Officer and Ofir Moreno, Ph.D., as SVP of Drug Discovery

Retrieved on: 
Monday, August 1, 2022
Biotechnology, Other Health, Health, Seniors, Pharmaceutical, Other Science, Research, Genetics, Consumer, Science, Clinical Trials, CA, Alembic, Infection, R, Bayer, Population, Biology, L.E.K. Consulting, Johnson & Johnson, Drug discovery, Dendreon, Neurodegeneration, Mechanical engineering, Prodrug, BS, CNS, Amgen, Multimedia, Marketing, Cellular senescence, Cell, AbbVie, Cell Chemical Biology, Merck, Boston Scientific, MBA, Ageing, Technology, Drug development, Senior, Mechanical, Patient, Metabolism, MEI, CBO, Growth, Cornell University, Pharmacy, Harvard University, List of life sciences, Pharmaceutical industry, Management, Chemistry, Rubedo, Neuroscience, Oncology, Immunology, Boston College, Northeastern University

View the full release here: https://www.businesswire.com/news/home/20220801005060/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220801005060/en/
    We are pleased to welcome Ali and Ofir, who bring invaluable experience and insights to our leadership team for this next stage of growth, said Marco Quarta, Ph.D., Chief Executive Officer and Co-Founder of Rubedo Life Sciences.
  • Im excited to join Rubedo at this important stage, as we advance our pipeline of potential best-in-class candidates targeting chronic age-related diseases, said Ali Siam, Chief Business Officer, Rubedo.
  • The team has developed a state-of-the-art computational platform to target senescent cells, said Ofir Moreno, Ph.D., Senior Vice President, Drug Discovery.
  • Ali Siam is Chief Business Officer (CBO) at Rubedo, where he leads business development and corporate strategy.

POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial

Retrieved on: 
Tuesday, June 21, 2022
Prostate cancer, COVID-19, Wilfrid Laurier University, MBA, Janssen, Ministry of Education (Malaysia), DuPont, Novartis Institute for Tropical Diseases, Commercial, Galena Biopharma, Cancer, Forward-looking statement, Private Securities Litigation Reform Act, Merck, Growth, Cell Chemical Biology, Abiraterone acetate, University, Novartis, GLOBE, Master of Science, SPLASH, Bachelor of Science, NASDAQ, Intention, Gallium, SEC, Radiopharmaceutical, Patient, Terminology, Biomedical Research, VP, Institute of Analytical Sciences, MCRPC, Rutgers Business School – Newark and New Brunswick, Advanced Accelerator Applications, Risk, Actinium-225, Pharmaceutical industry, Medical imaging, Bayer, Darolutamide

INDIANAPOLIS, June 21, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the appointment of Chris Horvath, as Executive Vice President, Commercial. Mr. Horvath brings almost twenty years of experience in the pharmaceutical industry, having led or worked on the launch of a number of key oncology products, including Pluvicto (lutetium 177Lu vipivotide tetraxetan), Locametz (gallium 68Ga gozetotide), Nubeqa (darolutamide), and Zytiga (abiraterone acetate). In his new role at POINT, Mr. Horvath will lead the commercial strategy for POINT’s pipeline.

Key Points: 
  • In his new role at POINT, Mr. Horvath will lead the commercial strategy for POINTs pipeline.
  • Mr. Horvath began his career as a scientist, working at both DuPont and Novartis Institutes for BioMedical Research.
  • He then transitioned to commercial roles of increasing responsibility at Janssen, Dendreon, Merck, Bayer, and most recently Advanced Accelerator Applications (Novartis).
  • Im extremely pleased to join the POINT Biopharma team and be a part of their next phase of growth, said Mr. Horvath.

Wayne Coyne of The Flaming Lips Expands Cannabis Brand Love Yer Brain to Michigan

Retrieved on: 
Friday, April 8, 2022
Brain, Sour Diesel, Royal Oak Music Theatre, Music, Plant, Cell Chemical Biology, The Flaming Lips, Weedmaps, Blind Pig (venue), THC, Green Apple, CEO, Edible, Cannabis, Instagram, Love, Biology, OH, Journal of Medical Marketing, Creativity, Rest, Amusement arcade, Chemistry

OKLAHOMA CITY, April 8, 2022 /PRNewswire-PRWeb/ -- Love Yer Brain, brainchild of Wayne Coyne of The Flaming Lips, has announced the expansion of its line of brain-shaped gummy edibles into the Michigan market with partner ErrlKing Concentrates, a leading cannabis extraction processor and manufacturer in the state.

Key Points: 
  • OKLAHOMA CITY, April 8, 2022 /PRNewswire-PRWeb/ -- Love Yer Brain , brainchild of Wayne Coyne of The Flaming Lips, has announced the expansion of its line of brain-shaped gummy edibles into the Michigan market with partner ErrlKing Concentrates , a leading cannabis extraction processor and manufacturer in the state.
  • "Love Yer Brain doesn't make you creative, we're presenting a product for people who are already creative.
  • Take a trip inside the brain of The Flaming Lips frontman, Wayne Coyne, with Love Yer Brain cannabis-infused edibles.
  • Love Yer Brain edibles represent the highest quality, potency, and consistency available, and Coyne is thrilled to bring his brand to new markets for more creatives to enjoy.